<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">978-1-60327-297-1</journal-id><journal-id journal-id-type="doi">10.1007/978-1-60327-297-1</journal-id><journal-id journal-id-type="nlm-ta">National Institute of Allergy and Infectious Diseases, NIH</journal-id><journal-title-group><journal-title>National Institute of Allergy and Infectious Diseases, NIH</journal-title><journal-subtitle>Volume 2;Impact on Global Health</journal-subtitle></journal-title-group><isbn publication-format="print">978-1-60327-296-4</isbn><isbn publication-format="electronic">978-1-60327-297-1</isbn></journal-meta><article-meta><article-id pub-id-type="pmc">7121647</article-id><article-id pub-id-type="publisher-id">7</article-id><article-id pub-id-type="doi">10.1007/978-1-60327-297-1_7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Virology</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Georgiev</surname><given-names>Vassil St.</given-names></name><degrees>PhD</degrees><address><email>vgeorgiev@niaid.nih.gov</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution-id institution-id-type="ISNI">0000000122975165</institution-id><institution>Department of Health &#x00026; Human Services, </institution><institution>National Institutes of Health, </institution></institution-wrap>6610 Rockledge Drive, Bethesda, MD 20892 USA </aff></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Georgiev</surname><given-names>Vassil St.</given-names></name><degrees>PhD</degrees><address><email>vgeorgiev@niaid.nih.gov</email></address><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution-id institution-id-type="ISNI">0000000122975165</institution-id><institution>Department of Health &#x00026; Human Services, </institution><institution>National Institutes of Health, </institution></institution-wrap>6610 Rockledge Drive, Bethesda, MD 20892 USA </aff></contrib-group><pub-date pub-type="ppub"><year>2009</year></pub-date><fpage>41</fpage><lpage>42</lpage><permissions><copyright-statement>&#x000a9; Humana Press, a part of Springer Science+Business Media, LLC 2009</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p>NIAD supports a broad spectrum of both basic and applied research in virology to expand the understanding of the biology, pathogenesis, and the immunology of viral diseases, leading to their prevention, control, and treatment, including research on (i) the viral replication cycle; (ii) the structure and function of the viral components; (iii) host virus interactions, including pathogenesis, immune evasion, and immune enhancement; (iv) viral genetics and evolution; (v) viral interference and defective interfering particles; (vi) virus vector relationships; (vii) epidemiology and natural history; and (viii) preclinical and clinical research to develop vaccines, adjuvants, therapeutics, immunomodulators, and diagnostics (<ext-link ext-link-type="uri" xlink:href="http://www3.niaid.nih.gov/research/topics/viral/introduction">http://www3.niaid.nih.gov/research/topics/viral/introduction</ext-link>.)</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>West Nile Virus</kwd><kwd>Severe Acute Respiratory Syndrome</kwd><kwd>Dengue Virus</kwd><kwd>Severe Acute Respiratory Syndrome</kwd><kwd>West Nile Virus Infection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Humana Press 2009</meta-value></custom-meta></custom-meta-group></article-meta></front><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Ali</surname><given-names>M.A.</given-names></name><name><surname>Cohen</surname><given-names>J.I.</given-names></name></person-group><article-title>Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread</article-title><source>Cell</source><year>2006</year><volume>127</volume><issue>2</issue><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.08.046</pub-id><pub-id pub-id-type="pmid">17055432</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.-S.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Paterson</surname><given-names>R.G.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name><name><surname>Jardetzky</surname><given-names>T.S.</given-names></name></person-group><article-title>Structure of the parainfluenza virus 5 F protein in its metastable, prefusion confirmation</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nature04322</pub-id><pub-id pub-id-type="pmid">16397490</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliphant</surname><given-names>T.</given-names></name><name><surname>Engle</surname><given-names>M.</given-names></name><name><surname>Nybakken</surname><given-names>G.E.</given-names></name><name><surname>Doane</surname><given-names>C.</given-names></name><name><surname>Johnson</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Gorlatov</surname><given-names>S.</given-names></name><name><surname>Mehlhop</surname><given-names>E.</given-names></name><name><surname>Marri</surname><given-names>A.</given-names></name><name><surname>Chung</surname><given-names>K.M.</given-names></name><name><surname>Ebel</surname><given-names>G.D.</given-names></name><name><surname>Kramer</surname><given-names>L.D.</given-names></name><name><surname>Fremont</surname><given-names>D., H.</given-names></name><name><surname>Diamond</surname><given-names>M.S.</given-names></name></person-group><article-title>Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus</article-title><source>Nat. Med.</source><year>2005</year><volume>11</volume><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/nm1240</pub-id><pub-id pub-id-type="pmid">15852016</pub-id></element-citation></ref></ref-list></back></article>